HIGH FATIGUE SCORES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A MULTIGROUP COMPARATIVE STUDY FROM THE COVAD E-SURVEY. (2022) Grignaschi S, Cavagna L, Kim M, R N, Lilleker JB, Sen P, Agarwal V, et al. Conference contribution COVID-19 VACCINATION-RELATED ADVERSE EVENTS AMONG AUTOIMMUNE DISEASE PATIENTS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY (2022) Sen P, R N, Nune A, Lilleker JB, Agarwal V, Kardes S, Kim M, et al. Conference contribution MANAGEMENT OF REFERRALS, TREATMENT STRATEGY, AND RESEARCH CHALLENGES IN POLYMYALGIA RHEUMATICA AMONGST RHEUMATOLOGISTS WORLDWIDE: A QUESTIONNAIRE BASED STUDY (2022) Donskov AO, Mackie S, Hauge EM, Gutierrez CT, Hansen I, Hemmig A, Van Der Maas A, et al. Conference contribution PREDICTING OUTCOMES IN SYSTEMIC SCLEROSIS: STRATIFICATION BY AUTO-ANTIBODIES OUTPERFORMS CUTANEOUS SUBSETTING IN THE EUSTAR COHORT (2022) Elhai M, Boubaya M, Sritharan N, Balbir-Gurman A, Siegert E, Hachulla E, De Vries-Bouwstra J, et al. Conference contribution CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS SINE SCLERODERMA: DATA FROM THE INTERNATIONAL EUSTAR DATABASE. (2022) Lescoat A, Huang S, Carreira P, Siegert E, De Vries-Bouwstra J, Distler J, Smith V, et al. Conference contribution GLUCOCORTICOIDS PRESCRIBING PRACTICES IN SYSTEMIC SCLEROSIS: AN ANALYSIS OF THE EUSTAR DATABASE. (2022) Iudici M, Mongin D, Siegert E, Carreira P, Distler J, Henes J, Zanatta E, et al. Conference contribution LONG-TERM SAFETY OF CANAKINUMAB IN PATIENTS WITH AUTOINFLAMMATORY DISEASES - INTERIM ANALYSIS OF THE RELIANCE REGISTRY (2022) Kuemmerle-Deschner JB, Henes J, Kortus-Goetze B, Kallinich T, Oommen P, Rech J, Krickau T, et al. Conference contribution PERSISTENT INFLAMMATION IN SYSTEMIC SCLEROSIS IS STRONGLY ASSOCIATED WITH SEVERE DISEASE AND MORTALITY: AN ANALYSIS FROM THE EUSTAR DATABASE (2022) Sarbu AC, Guler S, Stadler O, Allanore Y, Bernardino V, Distler J, Gabrielli A, et al. Conference contribution ABATACEPT DELAYS THE DEVELOPMENT OF RA-CLINICAL RESULTS AFTER 18 MONTHS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIAA STUDY IN RA-AT RISK PATIENTS (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Valor L, Tascilar K, Krönke G, et al. Conference contribution LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER (FMF) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY (2022) Henes J, Kuemmerle-Deschner JB, Krickau T, Kallinich T, Dressler F, Horneff G, Meier F, et al. Conference contribution